Dermira: Eli Lilly and Company Closes Acquisition of Dermira

Eli Lilly and Company (NYSE: LLY) completed its acquisition of Dermira, Inc. (NASDAQ: DERM). The acquisition expands Lilly's immunology pipeline with the addition of lebrikizumab, a novel, investigational, monoclonal antibody designed to bind IL-13 with high affinity that is being evaluated in a Phase 3 clinical development program for the treatment of moderate-to-severe atopic dermatitis [...]The post Eli Lilly and Company Closes Acquisition of Dermira appeared first on FinSMEs.